RT Journal Article
SR Electronic
T1 Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.05.20244590
DO 10.1101/2020.12.05.20244590
A1 Benedicto Crespo-Facorro
A1 Miguel Ruiz-Veguilla
A1 Javier Vázquez-Bourgon
A1 Ana C. Sánchez-Hidalgo
A1 Nathalia Garrido-Torres
A1 Jose M. Cisneros
A1 Carlos Prieto
A1 Jesus Sainz
YR 2020
UL http://medrxiv.org/content/early/2020/12/13/2020.12.05.20244590.abstract
AB Background Antipsychotics suppress expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the potential effects of aripiprazole (an FDA approved phenylpiperazine) on COVID19-related immunological parameters.Methods Differential gene expression profiles of non-COVID versus COVID RNA-Seq samples (CRA002390 project in GSA database) and drug-naïve patients with psychosis at baseline and after three months of aripiprazole treatment was identified. An integrative analysis between COVID and aripiprazole immunomodulatory antagonist effects was performed.Findings 82 out the 377 genes (21.7%) with expression significantly altered by aripiprazole have also their expression altered in COVID-19 patients and in 93.9% of these genes their expression is reverted by aripiprazole. The number of common genes with expression altered in both analyses is significantly higher than expected (Fisher’s Exact Test, two tail; P value=3.2e-11). 11 KEGG pathways were significantly enriched with genes with altered expression both in COVID-19 patients and aripiprazole medicated schizophrenia patients (P adj<0.05). The most significant pathways were associated to the immune system such as the “inflammatory bowel disease (IBD)” (the most significant pathway with a P adj of 0.00021), “Th1 and Th2 cell differentiation” and “B cell receptor signaling pathway”, all three related to the defense against infections.Interpretation This exploratory investigation may provide further support to the notion that protective effect is exerted by phenylpiperazine by modulating the immunological dysregulation associated to COVID-19. Along with many ongoing studies and clinical trials, repurposing available medications could be of use in countering SARS-CoV-2 infection, but require further studies and trials.Competing Interest StatementProf. Crespo-Facorro has received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Spanish Network for Research in Mental Health (CIBERSAM), from the 7th European Union Framework Program and Lundbeck. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson & Johnson, Mylan, Lundbeck, and Otsuka Pharmaceuticals. Dr. Ruiz-Veguilla has received unrestricted research funding from Instituto de Salud Carlos III. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen, Lundbeck, and Otsuka Pharmaceuticals. Dr. Vazquez-Bourgon has received unrestricted research funding from Instituto de Investigacion Marques de Valdecilla (IDIVAL). He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen-Cilag and Lundbeck. Carlos Prieto, Nathalia Garrido-Torres, Ana C. Sanchez-Hidalgo, and Jesus Sainz declare no conflicts of interest. Dr. Jose Miguel Cisneros has received honoraria as a speaker from Novartis, Astellas Pharma, Pfizer, MSD, Janssen Pharmaceuticals, and AstraZeneca, outside the submitted work. He has also received report grants from Instituto de Salud Carlos III, Spanish Government, co-financed by the European Development Regional Fund A way to achieve Europe, during the conduct of the study. Funding StatementThe present study was part of a larger prospective longitudinal study, the First Episode Psychosis Clinical Program 10 (PAFIP10) study. ClinicalTrials.gov Identifiers: NCT02200588, NCT03481465, and NCT03476473. No pharmaceutical industry or institutional sponsors participated in the study conception and design, data collection, analysis and interpretation of the results, or drafting of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cantabria Ethics Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe cohort to study the effect of aripiprazole on gene expression was obtained from Cantabria Biobank. The patterns of gene expression of non-COVID and COVID were obtained from CRA002390 project in GSA database